Saluggia, February 18th, 2011

CONCLUSION OF THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN SPA

On February 15th, 2011 DiaSorin announces the positive conclusion of the buy-back plan of 750,000 common shares, equal to 1.35% of the Company's share Capital for the purpose of new Stock-Options Plan of the Company under the terms and provisions authorized by the Shareholders Meeting dated April 27th, 2010.

The purchase was executed at a unit price not lower by more than 15% or higher by more than 15% than the official price posted for the DiaSorin shares during the Stock Market trading section that preceded each buy transaction.

For details on operations performed and any other requirement provided by the applicable Law please refer to the daily press already released as per the CE Regulation no. 2273/2003 as well as the Information Memorandum of the Board of Directors published by DiaSorin under applicable Law, also on the Company’s internet website www.diasorin.it.

The Chief Executive Officer

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.it

Contacts:

Investor Relations Officer
Laura Villa
DiaSorin S.p.A.
laura.villa@DiaSorin.it
+39 0161487532
+39 348 15 11 542

Press Office
Carolina Mailander
c.mailander@mailander.it
+39 335 655 56 51
Bruno Caprioli
capioli@mailander.it
+39 335 590 14 02